IC
ONCT

Ikarian Capital’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Ikarian Capital’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,509
Closed -$292K – 216
2022
Q1 		$292K Buy
10,509
+550
+6% +$20K 0.04% 156
2021
Q4 		$451K Hold
9,959
– – 0.07% 132
2021
Q3 		$830K Sell
9,959
-51
-0.5% -$4.22K 0.06% 163
2021
Q2 		$950K Sell
10,010
-13,006
-57% -$1.54M 0.08% 163
2021
Q1 		$3.83M Sell
23,016
-28,500
-55% -$3.77M 0.13% 148
2020
Q4 		$5.05M Buy
+51,516
New +$3.26M 0.22% 94

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $3.38B AUM 214.12% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return

Ikarian Capital's ONCT Position: Q2 2022 in Review

Ikarian Capital sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2022, closing a stake of 10,509 shares — an estimated $292K sold.

Ikarian Capital first reported a position in ONCT in Q4 2020 and held it in 6 quarters. The position peaked at $5.05M in Q4 2020. 75 funds tracked by Wall St. Rank hold ONCT as of Q2 2022.

  • Ikarian Capital reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 10,509 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $292K.
  • Ikarian Capital first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
  • Ikarian Capital's Oncternal Therapeutics, Inc. Common Stock position peaked at $5.05M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.